Animal Model Market Size - Animal Type (Mice, Rats, Fish, Birds), Technology (CRISPR, Microinjection), Application (Research & Development), Use (Human, Veterinary), End-use, (Companies, Contract Research Organizations), Forecast 2023 – 2032

Animal Model Market Size

Animal Model Market size was valued at USD 19.4 billion in 2022 and is estimated to progress at significant growth rate of 6.9% over the analysis timeframe. High growth of the market can be attributed to several factors such as rising adoption of animal models for biomedical research, surging expenditure & high investments in dug development & discover, growing focus on precision medicine, and extensive applications of animal models in healthcare industry.
 

As per the U.S. government statistics, in 2021, the number of laboratory animals employed in biomedical research were around more than 797,546, with a 2.2% surge as compared to 2019 and 2020. These statistics exclude the number of mice, rats, and fish models that are being used, which further adds up the number of animal models used for research.
 

Animal model can be defined as a non-human, living, genetically engineered animal that is used for scientific research purpose and investigation of human diseases. Also, these animal models are used for the purpose of better understanding of the human disease process without harming an actual human.

COVID-19 Impact

The emergence of COVID-19 was an unprecedented public health concern that has positively impacted the animal model market. Healthcare sector was also largely affected by the increasing prevalence of COVID-19 cases. However, heavy investments in research activities related to COVID-19 and the increased funding towards R&D activities to innovate novel therapeutics have promoted the use of animal models despite the pandemic.

Several pharmaceutical, biotechnology companies, and clinical research organizations revised their R&D spending to increase clinical trials to focus on the pandemic. Numerous animal models have been studied and employed to study COVID-19 infection. Mice were profoundly employed in infectious disease studies, especially SARS-CoV-2 strain adapted mice after deliberate passaging of virus in lung tissues. Due to such aforementioned factor, a positive impact was observed during the COVID-19 pandemic.

Animal Model Market Trends

The increasing number of pharmaceutical research and development activities is anticipated to drive the market progress. Need for novel drugs to help meet the unmet medical requirements are amongst the key value drivers of research-based pharmaceutical & biotechnology companies. The pharmaceutical sector develops several novel drugs that offer valuable clinical benefits. The surging number of investments by government as well as private players are amongst the prime variables driving the number of pharmaceutical research and development activities.

For instance, according to the Congressional Budget Office, in 2019, the pharmaceutical sector spent USD 83 billion in R&D activities. These expenditures comprises a comprehensive spectrum of activities, such as discovering & testing novel medications and testing for safety-parameters or regulatory purposes.

Animal Model Market Restraint

Stringent regulatory guidelines for animal model usage are put in place to ensure the ethical and responsible use of animals in scientific research. A framework of stringent regulatory and strict guidelines exists to ensure animal welfare. These regulations are exhaustive and vary from country to country. Regulatory guidelines typically require researchers to demonstrate the scientific necessity and potential benefits of using animal models. Research proposals involving animal experimentation are subject to ethical review by institutional animal care and use committees (IACUCs) or similar regulatory bodies. These committees assess the justification, design, and welfare considerations of the proposed studies. Such stringent & variable regulations may hamper the use of animal models in biomedical research, thereby hindering the business expansion.

Animal Model Market Analysis

By animal type, the animal model market is classified into mice, rats, fish, birds, cattle’s, pigs, amphibians, guinea pigs, dogs, cats, rabbits, monkey’s, sheep, hamsters, and other animal types. The mice segment dominated the market in 2022 with approximately 49.2% business share. Mice model is amongst the most common animal model used in studying human disease and human health. High phylogenetic similarities and physiological relatedness to humans, low maintenance, ease of breeding them in the laboratory, and easy availability of a number of inbred strains make mice models most predominantly used for research of human biology and disease.

Further, mice have a relatively short reproductive cycle and lifespan. This characteristic enables researchers to study multiple generations of mice in a relatively short period. Thus, several advantages offered by mice animal model is set to drive the segment trends.

Based on technology, the animal model market is segmented into CRISPR, microinjection, embryonic stem cell injection, nuclear transfer and other technologies. The CRISPR technology segment is anticipated to witness high growth at a CAGR of 7.3% during the forecast timeframe. The CRISPR technology has accelerated the development of transgenic animals, demonstrating an unprecedented efficiency and easy replicability, thereby limiting the time and expenses for genome editing. This technology has further enabled the production of animal models with more comprehensive genetic modifications as compared to conventional gene-targeting methods. Genome editing approach based on CRISPR system enables the accurate introduction of mutations at target DNA sequences. This technology has fuelled the generation of animal models and significantly contributed to their increased adoption for research purposes.

Based on application, the animal model market is segmented into research & development, production & quality control, academics, preclinical applications and other applications. The research & development segment held majority market share in 2022 and is expected to witness notable growth to reach USD 22.1 billion by 2032. The increasing number of research & development projects and rise in the investments to develop novel therapeutics is set to drive the segment share. Animal models are used to feature some of the earliest developments related with the disease and to detect potential drug targets.

Further, the pharmacokinetic and pharmacodynamic experiments are conducted for evaluating gastrointestinal absorption, distribution, metabolism, and drug excretion (ADME) parameters for every drug candidate. Animal models are extensively employed in these ADME studies that aid in screening these drug candidates to move forward to the next step in safety and efficacy studies.

Based on use, the animal model market is segmented into human and veterinary. The human segment accounted for largest revenue share in 2022 and is anticipated to grow at significant 7.0% growth rate during the analysis period. This significant segmental revenue is majorly attributed to the increasing prevalence of chronic disorders such as cancer in humans and increasing demand for personalized medicine. According to the World Health Organization (WHO), in 2020, cancer is amongst the critical conditions inflicting substantial disease burden, accounting for approximately 10 million deaths.

Similarly, as per the Cancer Statistics, in 2020, around 1.8 million new cancer cases were diagnosed in the U.S. alone. Therefore, the rise in the prevalence of such chronic human ailments is set to foster the demand for novel therapeutics and effective drugs. This demand in turn is expected to push the use of animal models in drug research & development, thereby propelling the segment outlook.

Based on end-use, the animal model market is segmented into companies, organizations, academic & research institutes and CRO’s. Companies segment accounted for highest segment share in 2022. Heavy investment in research and development by pharmaceutical & biotechnology companies and the surged usage of animal models in these activities is expected to fuel the segment expansion. According to a report by Johnson & Johnson, in 2019, the R&D spending surged by 5% and the major 11 pharma companies accounted for a total of USD 77.6 billion. Thus, animal models are regarded as an essential tool to aid in making the decision to develop potential therapies from preclinical studies to human trials. The rise in the investment and increased demand for effective therapeutics is set to drive the acceptance of animal models.

North America animal model market is projected to expand at 7.1% growth rate over the analysis timeframe. This is due to increasing investments and high number of clinical trials conducted in the region. The region is marked by the presence of major players operating in the mice model market which positively influences the market growth. Further, growing biomedical research in the U.S., and rising preclinical activities by contract research organizations (CROs) and pharmaceutical companies in the region will accelerate the market share. Thus, the rising number of clinical trials and significant investments into these studies is expected to boost the regional market size.

Animal Model Market Share

Major market players operating in the animal model market include:

• Charles River Laboratories, Inc.
• Envigo
• GenOway
• Harbor BioMed
• Trans Genic Inc.

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.

Animal Model Industry News:

• In March 2022, Charles River Laboratories signed an agreement with Hera Biolabs to breed, distribute, market, and sell Hera BioLabs' SRG rat to the global preclinical research community. This strategic move helped the company to diversify their product portfolio thereby increasing their geographical presence.
   
• In October 2021, JACKSON LABORATORY announced the acquisition of Charles River Laboratories, Japan. The acquisition is intended to extend the firm’s animal model business, including advanced immunodeficient models and humanized mice along with expanding the firm’s presence in Japan. The company's animal model solutions will benefit from this launch that will help them boost the business development.
   

The animal model market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Animal Type

• Mice
• Rats
• Fish
• Birds
• Cattles
• Pigs
• Amphibians
• Guinea Pigs
• Dogs
• Cats
• Rabbits
• Monkeys
• Sheep
• Hamsters
• Other animal types

By Technology

• CRISPR
• Microinjection
• Embryonic Stem Cell Injection
• Nuclear Transfer
• Other technologies

By Application

• Research & Development
• Infectious Disease
• Immunological Diseases
• Cancer
• Cardiovascular Diseases
• Diabetes
• Genetic Diseases
• Neurological Diseases
• Obesity
• NAFLD/NASH
• Renal Disease
• Diabetic Eye Disease
• Fibrosis
• Microbiome
• Other Research & Development Applications 
• Production and Quality Control
• Academics
• Preclinical Applications
• Infectious Disease
• Immunological Diseases
• Cancer
• Cardiovascular Diseases
• Diabetes
• Genetic Diseases
• Neurological Diseases
• Obesity
• NAFLD/NASH
• Renal Disease
• Diabetic Eye Disease
• Fibrosis
• Microbiome
• Other Preclinical Applications
• Other Applications

By Use

• Human
• Veterinary

By End-use

• Companies
• Pharmaceutical
• Biotechnology
• Cosmetics
• Other Companies 
• Organizations
• Government
• Non-government
• Academic and Research Institutes
• Contract Research Organizations (CRO)

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Netherlands
  • Czech Republic
  • Poland
  • Belgium
  • Finland
  • Hungary
  • Denmark
  • Ireland
  • Sweden
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Australia
  • South Korea
  • New Zealand
  • Taiwan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Rest of MEA